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Background: Using genome-wide genetic, gene expression, and microRNA expression (miRNA) data, we developed
an integrative approach to investigate the genetic and epigenetic basis of chemotherapeutic sensitivity.
Results: Through a sequential multi-stage framework, we identified genes and miRNAs whose expression correlated
with platinum sensitivity, mapped these to genomic loci as quantitative trait loci (QTLs), and evaluated the
associations between these QTLs and platinum sensitivity. A permutation analysis showed that top findings
from our approach have a much lower false discovery rate compared to those from a traditional GWAS of drug
sensitivity. Our approach identified five SNPs associated with 10 miRNAs and the expression level of 15 genes,
all of which were associated with carboplatin sensitivity. Of particular interest was one SNP (rs11138019), which
was associated with the expression of both miR-30d and the gene ABCD2, which were themselves correlated
with both carboplatin and cisplatin drug-specific phenotype in the HapMap samples. Functional study found
that knocking down ABCD2 in vitro led to increased apoptosis in ovarian cancer cell line SKOV3 after cisplatin
treatment. Over-expression of miR-30d in vitro caused a decrease in ABCD2 expression, suggesting a functional
relationship between the two.
Conclusions: We developed an integrative approach to the investigation of the genetic and epigenetic basis
of human complex traits. Our approach outperformed standard GWAS and provided hints at potential
biological function. The relationships between ABCD2 and miR-30d, and ABCD2 and platin sensitivity were
experimentally validated, suggesting a functional role of ABCD2 and miR-30d in sensitivity to platinating agents.
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Platinating agents are a commonly used, highly effective
family of chemotherapeutic agents. They are most fre-
quently used to treat various solid tumors of the testes,
bladder, ovaries, lung, head, and neck [1]. Response to
platinating agents varies from patient to patient; further-
more, severe toxicities are common among patients
receiving platinum therapy [2]. The ability to predict
platinum sensitivity among patients prior to treatment
has the potential to significantly improve cancer therapy.* Correspondence: rhuang@medicine.bsd.uchicago.edu
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unless otherwise stated.To this end, many biomarkers have been proposed to
predict either response or toxicities induced by plat-
inum [3]. However, most of these findings failed to be
validated in further studies, which suggest either false
discoveries or the lack of proper control for confound-
ing (for example, the wide range of cancer types studied
across varied tissue types). In this study, we developed a
novel analytical framework to overcome these chal-
lenges and performed gene-knockdown and microRNA
(miRNA) overexpression experiments to functionally
validate our findings.
Recent advances in genomic technology have enabled
genome-wide interrogation of genetic variations for
their contribution to complex traits, including diseaseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pretation of genome-wide association study (GWAS)
findings currently remains difficult, because association
tests yield little biological insight into the mechanisms
for the observed relationships. To address these issues,
several alternative analyses have been proposed in place
of simple genotype-phenotype associations, including
methods that integrate transcriptome expression quan-
titative trait loci (eQTL) into GWASs [4,5]. These
methods not only facilitate the selection of variants with
prior functional support for subsequent follow-up stud-
ies, but crucially, they propose biological mechanisms
underlying the identified genotype-phenotype associa-
tions. As analytical methods that utilize high-throughput
molecular phenotypes (“omics” data) to elucidate the func-
tional basis of GWAS findings are refined, miRNAs
have been increasingly recognized as an important
class of regulatory molecules [6] affecting a wide var-
iety of cellular processes [7] and playing important
roles in disease pathogenesis, including cancer [8].
Consequently, we hypothesized that inclusion of this
epigenetic information into large-scale association
studies may yield an even finer resolution of the bio-
logical pathways underlying platinum sensitivity.
The relatively well-understood mechanism of action
for platinum-based antineoplastic agents is to cause
cross-linking of DNA, which results in inhibition of
DNA synthesis and repair. Not surprisingly, this in-
hibitory activity is highly effective at disrupting prolif-
eration of rapidly growing cell types. Although cancer
cells tend to grow significantly faster than most normal
tissues, variability in tumor growth as represented by
disease progression is commonly observed among dif-
ferent types of cancer as well as among patients with
the same type of cancer. Variability in cellular growth
rates can be quantified, and has been shown to be a
heritable trait with its own genetic and epigenetic
markers [9]. Because of the platinums’ causal effect on
growth, it can be difficult to tease apart the drug-
specific effect from individual variability in response
attributable to differential cellular growth patterns. In
this study, we developed a platinum-sensitivity-specific
phenotype that is independent of cellular growth rate.
We hypothesized that such a phenotype would allow
us to identify genetic predictors specific to platinum
sensitivity.
The goal of the current study was to utilize the com-
plex relationships between genetic variation, miRNA
expression, and mRNA expression to shed light on a
particular complex trait of enormous pharmacologic
importance, cellular sensitivity to the platinating
agents. We chose to focus on a platinum sensitivity
phenotype that was measured in a set of International
HapMap cell lines. These HapMap cell lines present amodel system that provides publicly available genome-
wide genetic as well as additional omics data, along




International HapMap YRI (Yoruba from Ibadan, Nigeria)
lymphoblastoid cell lines (LCLs) were purchased from the
Coriell Institute for Medical Research (Camden, NJ). Of
these, 90 YRI I/II (HAPMAPPT03) samples were utilized
for genome-wide discovery. LCLs were maintained in
RPMI 1640/1% l-glutamine plus 15% FBS as previously
described [14]. SKOV-3, an ovarian cancer cell, was
purchased from ATCC and maintained according to
ATCC's recommendations.
Genotype data and expression profiling
For all cell lines, genome-wide information in the form of
single nucleotide polymorphism (SNP) genotypes was
downloaded from www.HapMap.org (ref27). Global
baseline transcriptional gene expression and miRNA
expression levels were quantified and reported previ-
ously [10,12] and all data were downloaded from GEO
(GSE7761 and GSE34406, respectively).
Genome-wide integrative pyramid analysis
In this study, the pyramid analysis (Figure 1) was applied
to carboplatin and cisplatin separately. The pyramid ana-
lysis is a six-stage analytic framework. The first 3 stages
involve identifying mRNAs and miRNAs relevant to the
trait under study:
Y i ¼ β0 þ β1Ti þWiγ




Y i ¼ λ0 þ λ1Mi þWiγ




Ti ¼ ν0 þ ν1Mi
þ εi with εieN 0; σ2
 
and ν1
< 0 miRNA−mRNA regulatory relationshipð Þ ð3Þ
We identified mRNAs (e.g., in the notation above, a
gene T such that Ti is the expression level for the i-th
individual) and miRNAs (e.g., again, in the notation
above, a miRNA M such that Mi is the expression level
for the i-th individual) with expression effect (i.e., β1 and
λ 1 are non-zero) on the trait (stage 1 and 2). The Wi, in
this framework, provides the non-genomic covariates
for the i-th individual. Such covariates may include
Figure 1 Overview of integrative pyramid analysis schema for the genome-wide discovery. Each stage (represented by an edge of the
pyramid) represents a model describing the relationship between the two variables (represented by the nodes for the edge). Each stage uses only
the data inherited from the previous stages which may have utilized certain thresholds for inclusion criteria. Thus, the filtering stages (stages 1-5)
form a series of biologically relevant steps that result in a reduction in the number of SNP tested at the genetic association testing stage (stage 6)
and therefore a potential increase in power. A permutation procedure (see Methods) that accounts for the fact that the samples for the filtering
stages may overlap with the samples used at the genetic association testing stage was used to evaluate the overall significance of the resulting
SNPs. For each replicate derived from the application of the pyramid analysis to a permuted dataset (in our analysis, n = 1000), we obtain a list of
SNPs and p-values for association with the trait (designated here as p1, p2, p3, etc.). We utilize these sets of p-values derived from permuted datasets to
estimate the null distribution.
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analyses) and hidden variables (such as derived from
PEER [15]. In stage 3, we further reduced the list of
genes and miRNAs of interest by restricting our results
to only those gene/miRNA pairs whose expression
levels are negatively correlated, under the assumption
that miRNA regulatory activity acts mostly through the
down-regulation of gene targets. Once the list of genes and
miRNAs of interest (which we refer to as “functional units”)
was identified from these stages, we performed genome-
wide association tests between all SNPs and the functional
units assuming an additive genetic model. For the k-th SNP
Sk, we performed the following QTL mapping analyses:
Ti ¼ π0 þ π1Ski þWiμ




Mi ¼ π0 þ π1Ski þWiμ
þ εi with εieN 0; σ2
 
miRNA QTL mappingð Þ
ð5Þ
Finally, the SNPs that were found to be associated with
the functional units from these QTL mapping analyseswere examined for their association with phenotype by
testing H0: δ 1 = 0.
Y i ¼ δ0 þ δ1Ski þWiθ
þ ε i with εie N 0; σ2
 
genetic association testingð Þ
ð6Þ
In our particular implementation of the pyramid ana-
lysis, we chose p < 0.05 in stages 1 and 2 to select the
trait-associated genes and miRNAs. For the miRNA-
mRNA negative correlations, a p-value of 10-4 was used,
which, in our dataset, was equivalent to an FDR of 0.05
on the genome-wide scale. These filtering steps signifi-
cantly decreased the number of subsequent SNP tests
performed. The (potentially arbitrary) threshold chosen
at each stage of the pyramid analysis may of course yield
results that are not overall significant; furthermore, the
filtering steps (stage 1-5) were done on the same set of
samples as those on which the test (at the final stage) for
SNP association was done. We therefore evaluated the
overall significance of the resulting SNPs through a
permutation-based false discovery rate (see next section).
We should note that our method facilitates the use of a
user-defined threshold at each stage of the analysis, and
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tion of the overall significance.
Performance evaluation: traditional GWAS vs. pyramid
analysis
To evaluate the performance of the pyramid analysis, we
compared the distribution of p-values identified through
traditional GWAS and that obtained from our pyramid
analysis. Furthermore, to evaluate whether the inclusion
of miRNA expression could yield additional performance
gain, we examined the association p-value distribution
for those SNPs previously associated with mRNA ex-
pression alone. Applied to the pyramid analysis, the
traditional FDR approach [16], which assumes a uniform
null distribution, may produce misleading results [17].
Therefore, we designed a permutation-based method
that utilizes the empirical null distribution to evaluate
the (empirical) FDR when multi-dimensional datasets
are involved. In this method, we performed permutation
analyses, permuting (n = 1000) the trait value under in-
vestigation (e.g., platinum sensitivity) while maintaining
the correlation structure of the omics phenotypes and
preserving the pyramid stages outlined above for each
permuted dataset, to arrive at an empirical significance
for the resulting list of SNPs [17]. Importantly, our
permutation-based method accounts for the potentially
arbitrary threshold used at each stage of the pyramid
analysis.
Platinating-agent-specific cellular sensitivity phenotypes
LCLs were treated with increasing dosage of either car-
boplatin or cisplatin for 72 and 48 hours, respectively.
Cellular growth inhibition was measured using an
Alamar Blue assay as described previously [18]. Drug
concentration required to inhibit 50% of cellular growth is
defined as IC50 and was used to characterize individual
cellular sensitivity to the platinum agents. IC50 data was
reported elsewhere [14,19] and data have been deposited
into www.PACdb.org [20].
The intrinsic growth rate (iGrowth) of over 500 Hap-
Map cell lines derived from a mixed-effects model has
been described elsewhere [9]. We modeled a platinating
agent’s IC50 and decomposed it as a sum of iGrowth and
a drug-specific phenotype (DSP) that is independent of
intrinsic growth:
Y i ¼ iGrowthi þ DSPi þ εi with εieN 0; σ2
 
Thus, to obtain the DSP, a linear model was fit be-
tween iGrowth and log2IC50 with iGrowth as the inde-
pendent variable. This model was fit separately for
both carboplatin and cisplatin. The residuals from this
model fit were used as the DSP in further analysis.
Although our primary interest here was in the resultsof the pyramid analysis of the drug-specific component,
the method can be applied to the analysis of general
platinum sensitivity including cellular proliferation as
well.
Functional validation of miR-30d, ABCD2 and platinum
sensitivity
We performed ABCD2 siRNA knockdown and miR-30d
over-expression experiments in SKOV-3 using Dharma-
FECT Transfection Reagent 1 and existing Dharmacon
DharmaFECT General Transfection protocol (Thermo
Scientific). siRNA for ABCD2 (a set of 4 unique siRNAs
cat. #1027416), miR-30d mimic (cat. #MSY0000245),
and scramble control siRNA (AllStars Negative control,
cat. #1027292) were purchased from Qiagen (Valencia,
CA). Specifically, 6000 cells/well were plated in 96-well
plates 24 hours prior to transfection. 100 μl of transfec-
tion media that contained 40nM siRNA, miRNA mimic,
scramble control, or water (for mock transfection con-
trol), 0.4μl DharmaFECT transfection reagent 1, and
standard SKOV-3 growth media were added to each well
of the 96-well plate. Six hours later, transfection media
was removed and replaced with regular growth media or
media containing increasing concentrations of cisplatin
(0uM, 5uM, and 10uM). Caspase-3 and caspase-7 activ-
ity levels were measured 24 hours post drug treatment
via Caspase-Glo 3/7 Assay (Qiagen). A Student’s t-test
was conducted to compare the percent caspase activity
induced by cisplatin after treating the cells with either
ABCD2 siRNA, miR-30d mimic, or scramble control at
each concentration. P < 0.05 was used to define statistical
significance.
To confirm transfection efficiency and examine the ef-
fect of miR-30d over-expression on ABCD2 expression,
SKOV-3 cells were plated at 0.25 × 106 cells/well in 6-
well plates, transfected with 40nM siRNA, miRNA
mimic, scramble control or water using 8 uL of Dharma-
FECT transfection reagent 1 in 2 mL of transfection
media per well. Cells were collected in 350 uL of QIAzol
Lysis Reagent (Qiagen) per well and like wells were
pooled. Knockdown of ABCD2 was confirmed by qPCR
of ABCD2 gene under the ABCD2 siRNA, miR-30d
mimic, and scramble conditions at 24 hours after trans-
fection using Applied Biosystems Taqman primer/probe
sets. miR-30d overexpression was confirmed by quanti-
tative PCR (qPCR) using primers purchased from Exiqon
(Woburn, MA). Details for total RNA isolation, cDNA
conversion and PCR conditions were described previ-
ously [21]. Real-time PCR was conducted using an ABI
Vii7 thermocycler (Applied Biosystems, Foster City,
CA). A Student’s t-test was conducted between the
scramble control treated cells and either the siRNA or
mimic treated cells with p < 0.05 being considered sta-
tistically significant.
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Genome-wide integrative pyramid analysis
We developed and implemented a genome-wide analytic
approach that integrates transcriptional gene expression
and miRNA expression to identify robust SNP associa-
tions with IC50 (drug concentration required to inhibit
50% of cellular growth) in response to carboplatin or
cisplatin treatment (evaluated separately). The overall
workflow is illustrated in Figure 1; we refer to this
throughout as a “pyramid analysis” (see Methods for
detailed and precise description). The initial stage is to
identify functional units that are important for the
phenotype of interest (in this case, the functional units
are genes and miRNAs that are negatively correlated
with each other, reflecting putative regulatory relation-
ships, and, in addition, have expression levels that are
correlated with the drug sensitivity phenotype). Genetic
factors that are associated with these functional units as
quantitative trait loci (QTLs) [12,22,23] were identified
and evaluated against the phenotype. By restricting to
only those genetic variants that may be of functional
significance as QTLs, we reduced the multiple testing
burden in the pyramid analysis compared to traditional
GWAS analysis. Furthermore, the identified genetic sig-
nals are, by definition, already related to functional units,
which thus provide mechanistic hypotheses for the
observed genotype-phenotype associations.
To test the performance of this function-based ap-
proach, we compared the false discovery rate (FDR) (see
Methods) for the genotype-phenotype associations de-
rived from three different methods (namely, the trad-
itional GWAS approach, analysis performed using onlyFigure 2 QQ plots for association with the carboplatin and cisplatin I
all SNPs from traditional GWAS. Blue circles are the SNP associations with d
associated with mRNA expression. Red circles show SNP associations deriveSNPs associated with gene expression as eQTLs, and the
pyramid analysis as defined above) against carboplatin
and cisplatin IC50, performed separately. As shown in
Figure 2, using the SNPs filtered in stage 5 of the pyra-
mid model (red dots), by virtue of their association with
gene and miRNA expression, we identified SNPs associ-
ated with both carboplatin and cisplatin sensitivity with
a lower FDR than SNPs derived from traditional GWAS
or from the eQTL-based analysis. Notably, traditional
GWAS yielded no significant findings due to the large
number of statistical tests.Applying the pyramid analysis to platinum-agent-specific
phenotypes
Carboplatin and cisplatin IC50 values were highly cor-
related with intrinsic growth rate (iGrowth) in the
HapMap LCL samples (p <0.0001 for both carboplatin
and cisplatin, Figure 3A) with faster cellular growth
corresponding to lower IC50, representing higher sen-
sitivity to the platinums. To control for the effect of
growth rate, we developed drug-specific phenotypes
(DSPs) for both carboplatin and cisplatin by using the
residual of iGrowth from the IC50 drug sensitivity
phenotype (see Methods). We observed that DSP
remained highly correlated with the original platinum
IC50 phenotype (p <0.0001, r
2 = 0.6088 and p <0.0001,
r2 = 0.5146 for carboplatin and cisplatin respectively,
Figure 3B) but, as expected, was no longer correlated
with iGrowth (p = 1.0, r2 = 5.003 × 10-16 and p = 1.0,
r2 = 1.314 × 10-18 for carboplatin and cisplatin respect-
ively, Figure 3C).C50. A) carboplatin; B) cisplatin. Black circles show the associations for
rug sensitivity derived from restricting the analysis to only those SNPs
d from the pyramid method.
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Figure 3 Platinum-specific phenotype. A) Carboplatin and cisplatin IC50 values vs intrinsic growth rate p <0.0001 r
2 = 0.3912 (carboplatin) and
p <0.0001 r2 = 0.4854 (cisplatin). B) Carboplatin and cisplatin drug specific phenotypes (DSPs) vs. intrinsic growth rate p = 1.0 r2 = 5.003 × 10-16
(carboplatin) and p = 1.0 r2 = 1.314 × 10-18 (cisplatin). C) Carboplatin and cisplatin IC50 values vs corresponding DSPs p <0.0001 r
2 = 0.6088
(carboplatin) and p <0.0001 r2 = 0.5146 (cisplatin).
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and cisplatin DSPs instead of IC50s this time. The results
of these pyramid analyses are shown in Table 1. For
carboplatin, we identified 5 SNPs associated with the
expression of 10 miRNAs and 15 genes, each correlated
with the carboplatin DSP in the discovery samples. Simi-
larly, for cisplatin, we identified 1 SNP associated with
the expression of 1 miRNA and 1 gene, each correlated
with the cisplatin DSP in the discovery samples. Not-
ably, the single SNP-miR-gene relationship (namely,
rs11138019 genotype, miR-30d expression, and ABCD2
expression) seen for cisplatin was also found for carbo-
platin (shown in bold in Table 2). Specifically, ABCD2
mRNA expression was found to correlate with both
DSPs in the discovery samples (Figure 4A, p = 0.019 and
p = 0.030 for carboplatin and cisplatin, respectively). We
also identified a positive correlation between miR-30d
expression and the platinum DSPs (p = 0.004 and p =
0.020 for carboplatin and cisplatin respectively Figure 4B).ABCD2 mRNA expression and miR-30d expression were
found to be negatively correlated at p = 8.57 × 10-5
(Figure 4C), suggesting a regulatory relationship. The
SNP rs11138019 was correlated with ABCD2 expres-
sion at p = 3.00 × 10-5 (Figure 4D) and with miR-30d
expression at p = 0.044 (Figure 4E). rs11138019 geno-
type was also correlated with both DSPs at p = 3.28 ×
10-5 for carboplatin and p = 2.598 × 10-5 for cisplatin
(Figure 4F).
Functional validation of miR-30d, ABCD2 and platinum
sensitivity
We conducted a gene knockdown experiment of ABCD2
in SKOV-3 in which the addition of ABCD2 siRNA
resulted in decreased expression of ABCD2 mRNA
compared to control (data not shown; after transfection
with 40nM ABCD2 siRNA, ABCD2 expression was no
longer quantifiable by qPCR) and consequently in-
creased cisplatin-induced cellular apoptosis, as shown
Table 1 Pyramid analysis summary results for carboplatin- and cisplatin-DSP in HapMap YRI samples
Analysis Threshold for
data filtering
Unique number of findings
carboplatin Cisplatin
Stage 1 DSP – mRNA expression correlation <0.05 829 genes (832 TCs) 913 genes (918 TCs)
Stage 2 DSP – miRNA expression correlation <0.05 34 miRNA 20 miRNAs
Stage 3 Inverse correlation between miRNA and mRNA expression <0.0001 141 genes 18 genes
27 miRNAs 7 miRNAs
Stage 4 SNP-mRNA association ≤0.0001 51777 SNPs 9416 SNPs
141 genes 17 genes
Stage 5 SNP-miRNA association <0.05 38289 SNPs 5437 SNPs
27 miRNAs 7 miRNAs
Stage 6 SNP-DSP association ≤0.0001 9 SNPs 2 SNPs
16 genes 2 genes
19 miRNAs 5 miRNAs
Final assembly 5 SNPs 1 SNP
15 genes 1 gene
10 miRNAs 1 miRNA
DSP stands for drug-specific phenotype. TC stands for transcript cluster ID.
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μM cisplatin (Figure 5A, p = 0.013). When SKOV-3 cells
were transfected with miR-30d mimic, we observed an in-
crease in miR-30d expression (Figure 5B, p = 0.001) and a
decrease in ABCD2 expression (Figure 5C, p = 0.047).
Cisplatin-induced cellular apoptosis showed a trend in
the same direction as with ABCD2 siRNA, however the
effect was not significant (p > 0.05).
Discussion
Building on the successes of GWAS for mapping com-
plex traits, considerable efforts have been invested in the
development of new methods to decipher the contribu-
tion of genetic variants that have modest effects on
phenotype. One reasonable approach is to prioritize
SNPs with prior functional support from increasingly
available omics studies. This method is supported by
previous studies that demonstrated that reproducible
GWAS findings for human complex traits are more
likely to fall in loci with gene/miRNA regulatory effects
in the form of mRNA and miRNA expression quantita-
tive trait loci (m-eQTLs and mi-eQTLs) [4,5,12]. In this
study, utilizing multiple high-throughput genome-wide
datasets, we developed an integrative approach that in-
corporates mRNA and miRNA regulatory elements as
well as genetic variation to gain mechanistic insight into
platinum sensitivity.
To compare the performance of our integrative pyramid
analysis to that of traditional GWAS, we compared the
p-value distribution between these analytic approaches.
We found that the use of our pyramid approach, which
prioritizes SNPs with prior functional support fromstudies of high-throughput molecular phenotypes (i.e.,
both mRNA and miRNA expression), substantially im-
proved power to detect significant associations with plat-
inum sensitivity. Importantly, for both carboplatin and
cisplatin, the use of mRNA data in defining functionally
important SNPs for inclusion in downstream analyses per-
formed better than the simple use of whole-genome SNP
data, and the further refinement with the inclusion of
miRNA expression information further improved per-
formance. Indeed, at FDR < 0.10, no significant SNP asso-
ciation with cisplatin IC50 was found under traditional
GWAS; however, using the pyramid analysis, we identified
2 SNPs significantly associated with cisplatin sensitivity at
FDR < 0.10, and, indeed, the most significant SNP reached
FDR < 0.05. These results demonstrate the substantial gain
in power from an application of the pyramid analysis, at
least for some traits, despite the small sample size. We
realize that some variants may be missed by the method
proposed here, which explicitly enriches for SNPs regu-
lating miRNAs and mRNAs with the additional require-
ment that the miRNA and mRNA are in a specific
regulatory relationship. Nevertheless, the substantially
improved signals from our analyses relative to trad-
itional unbiased GWAS, for both platinating agents,
suggest the importance of these regulatory relationships
underlying platinum sensitivity.
Over the years, numerous studies have been conducted
to discover robust predictors of platinum response and/or
toxicity. Unfortunately, many of the identified biomarkers
have failed to replicate under further interrogation. One of
the reasons that this may be the case is that, due to its pre-
sumed mechanism of action, the efficacy of platinating
Table 2 The pyramid analysis results for carboplatin in HapMap YRI samples












rs11138019 hsa-miR-181a ABCD2 3.28E-05 7.22E-03 3.00E-05 6.93E-03 3.47E-06 1.88E-02
DDR2 1.00E-05 4.00E-02 5.72E-03
ECOP 1.00E-04 5.91E-03 2.31E-03
EIF2AK3 1.00E-05 2.00E-02 1.54E-02
HMOX1 1.00E-04 1.65E-04 3.76E-02
HSPC159 7.00E-05 1.10E-04 1.27E-02
LARGE 5.00E-05 1.96E-05 1.05E-03
PDK2 3.00E-05 1.49E-04 2.44E-02
PIK3R5 1.00E-04 4.32E-03 1.86E-02
RBM47 1.00E-04 1.00E-02 5.55E-03
USP53 2.00E-05 8.56E-05 4.77E-02
hsa-miR-181b ABCD2 1.26E-02 3.00E-05 1.17E-02 4.70E-06 1.88E-02
ECOP 1.00E-04 3.38E-03 2.31E-03
EIF2AK3 1.00E-05 2.00E-02 1.54E-02
HMOX1 1.00E-04 3.56E-04 3.76E-02
HSPC159 7.00E-05 5.84E-04 1.27E-02
LARGE 5.00E-05 6.74E-05 1.05E-03
MEF2D 4.00E-05 4.00E-02 7.53E-03
PDK2 3.00E-05 1.81E-04 2.44E-02
PIK3R5 1.00E-04 4.60E-03 1.86E-02
RBM47 1.00E-04 1.00E-02 5.55E-03
USP53 2.00E-05 8.32E-05 4.77E-02
hsa-miR-19b ECOP 2.71E-02 1.00E-04 9.82E-04 1.00E-02 2.31E-03
EIF2AK3 1.00E-05 1.76E-03 1.54E-02
HMOX1 1.00E-04 1.46E-03 3.76E-02
LARGE 5.00E-05 4.00E-02 1.05E-03
MEF2D 4.00E-05 2.35E-03 7.53E-03
PDK2 3.00E-05 1.00E-02 2.44E-02
RBM47 1.00E-04 5.92E-03 5.55E-03
hsa-miR-20b ABCD2 2.90E-02 3.00E-05 9.45E-05 1.00E-02 1.88E-02
DDR2 1.00E-05 2.00E-02 5.72E-03
ECOP 1.00E-04 4.76E-04 2.31E-03
EIF2AK3 1.00E-05 3.41E-05 1.54E-02
HMOX1 1.00E-04 2.55E-03 3.76E-02
HSPC159 7.00E-05 2.00E-02 1.27E-02
LARGE 5.00E-05 1.93E-04 1.05E-03
MEF2D 4.00E-05 1.11E-04 7.53E-03
PDK2 3.00E-05 2.38E-05 2.44E-02
PIK3R5 1.00E-04 8.33E-03 1.86E-02
RBM47 1.00E-04 4.48E-04 5.55E-03
USP53 2.00E-05 3.00E-02 4.77E-02
hsa-miR-30d ABCD2 4.42E-02 3.00E-05 3.80E-03 8.57E-05 1.88E-02
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Table 2 The pyramid analysis results for carboplatin in HapMap YRI samples (Continued)
DDR2 1.00E-05 3.55E-05 5.72E-03
ECOP 1.00E-04 3.52E-03 2.31E-03
HMOX1 1.00E-04 3.09E-03 3.76E-02
HSPC159 7.00E-05 4.68E-04 1.27E-02
LARGE 5.00E-05 1.00E-02 1.05E-03
PDK2 3.00E-05 1.00E-02 2.44E-02
PIK3R5 1.00E-04 1.46E-03 1.86E-02
USP53 2.00E-05 3.12E-04 4.77E-02
hsa-miR-363 ABCD2 1.28E-02 3.00E-05 1.13E-03 1.74E-04 1.88E-02
DDR2 1.00E-05 3.94E-05 5.72E-03
ECOP 1.00E-04 3.00E-02 2.31E-03
EIF2AK3 1.00E-05 4.00E-03 1.54E-02
HSPC159 7.00E-05 1.35E-03 1.27E-02
LARGE 5.00E-05 1.07E-05 1.05E-03
MEF2D 4.00E-05 1.00E-02 7.53E-03
PDK2 3.00E-05 1.36E-04 2.44E-02
PIK3R5 1.00E-04 1.66E-06 1.86E-02
USP53 2.00E-05 3.99E-06 4.77E-02
rs4919716 hsa-miR-20b ECOP 1.95E-05 3.00E-02 9.00E-05 9.45E-05 4.76E-04 2.31E-03
FURIN 1.00E-04 3.00E-02 4.27E-02
MTMR14 8.00E-05 7.63E-03 1.73E-02
hsa-miR-30b ECOP 4.09E-02 9.00E-05 7.08E-03 3.57E-03 2.31E-03
FURIN 1.00E-04 2.43E-05 4.27E-02
MTMR14 8.00E-05 5.77E-03 1.73E-02
hsa-miR-30d ECOP 2.10E-02 9.00E-05 3.80E-03 3.52E-03 2.31E-03
FURIN 1.00E-04 1.69E-05 4.27E-02
MTMR14 8.00E-05 1.00E-02 1.73E-02
hsa-miR-339-5p ECOP 1.12E-02 9.00E-05 1.31E-02 9.37E-03 2.31E-03
FURIN 1.00E-04 2.36E-03 4.27E-02
MTMR14 8.00E-05 3.42E-03 1.73E-02
hsa-miR-363 ECOP 2.64E-02 9.00E-05 1.13E-03 3.00E-02 2.31E-03
FURIN 1.00E-04 2.33E-06 4.27E-02
MTMR14 8.00E-05 5.69E-04 1.73E-02
rs7670734 hsa-let-7i TP63 5.21E-05 2.20E-02 8.00E-05 2.44E-03 5.08E-05 3.95E-02
hsa-miR-20b TP63 4.26E-02 9.45E-05 1.00E-02
hsa-miR-25 TP63 1.11E-02 1.65E-02 1.00E-02
hsa-miR-339-5p TP63 1.07E-02 1.31E-02 5.44E-04
hsa-miR-363 TP63 2.48E-02 1.13E-03 1.76E-06
rs7677704 hsa-let-7i TP63 5.21E-05 2.20E-02 8.00E-05 2.44E-03 5.08E-05 3.95E-02
hsa-miR-20b TP63 4.26E-02 9.45E-05 1.00E-02
hsa-miR-25 TP63 1.11E-02 1.65E-02 1.00E-02
hsa-miR-339-5p TP63 1.07E-02 1.31E-02 5.44E-04
hsa-miR-363 TP63 2.48E-02 1.13E-03 1.76E-06
rs9312445 hsa-let-7i TP63 5.21E-05 2.20E-02 8.00E-05 2.44E-03 5.08E-05 3.95E-02
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Table 2 The pyramid analysis results for carboplatin in HapMap YRI samples (Continued)
hsa-miR-20b TP63 4.26E-02 9.45E-05 1.00E-02
hsa-miR-25 TP63 1.11E-02 1.65E-02 1.00E-02
hsa-miR-339-5p TP63 1.07E-02 1.31E-02 5.44E-04
hsa-miR-363 TP63 2.48E-02 1.13E-03 1.76E-06
Overall significance was evaluated using permutations.
*Overlap with cisplatin pyramid analysis is shown in bold.
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which may lead to very variable results across multiple cell
and tissue types. Since the platinums are used in the
treatment of a wide variety of cancer types, an approach
that separates platinum-specific effects and the intrinsic
growth rates of different tumors may provide a more
robust phenotype in identifying biomarkers that can
predict platinum sensitivity independent from cell types.
In this study, we developed a DSP which accounted for
the contribution of growth rate in cellular response to
cisplatin and carboplatin in our discovery cell lines.
Given the enormous amount of genomic information
available, utilizing the HapMap LCLs as our discovery
set allowed us to generate this new and novel phenotype,
which would be difficult in a smaller or less homogenous
sample set.
Through our integrative pyramid analysis, we identi-
fied a SNP (rs11138019) associated with the expression

















































ca rb o p la tin
c is p la tin










c a rb o p la t in
c isp la tin
A
D
Figure 4 Findings from pyramid analysis. A) ABCD2 expression vs. carbo
(cisplatin). B) miR-30d expression vs. carboplatin and cisplatin drug specific
C) miR-30d expression vs. ABCD2 expression p = 8.57 × 10-5. D) rs11138019 ge
miR-30d expression p = 0.044. F) rs11138019 genotype vs. carboplatin and cisand mRNA correlated with both carboplatin- and
cisplatin- specific sensitivity in the HapMap LCL sam-
ples. miR-30d has been shown to play an important role
in several biological processes related to cancer devel-
opment and progression. For example, miR-30d has
been suggested to be an oncomir, regulating tumor cell
proliferation [24], and senescence through regulation of
tumor suppressor gene p53 [25]. miR-30d is associated
with poor clinical outcomes in ovarian cancer patients
[26], and has been identified as a potential prognostic
marker of prostate cancer [27]. It has also been shown
to enhance invasion and immuno-suppression during
metastasis through regulation of GalNAx transferases
[28]. A recent study reported that miR-30d was ampli-
fied in more than 30% of multiple types of human solid
tumors [26], suggesting a therapeutic role of the plati-
nums in these cancers.
In our study, we did not observe significantly in-
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platin and cisplatin DSPs p = 0.019 (carboplatin) and p = 0.030
phenotypes (DSPs) p = 0.004 (carboplatin) and p = 0.020 (cisplatin).
notype vs. ABCD2 expression p = 3.00 × 10-5. E) rs11138019 genotype vs.
platin DSPs p = 3.28 × 10-5 (carboplatin) and p = 2.60 × 10-5 (cisplatin).
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Figure 5 Functional validation of ABCD2 and miR-30d. A) Increase in cisplatin-induced apoptosis 24 hours after transfection with 40nM ABCD2
siRNA as compared to scrambled control siRNA (p = 0.013). B) Increased miR-30d expression 24 hours after transfection with 40nM miR-30d mimic
(normalized to RNU6 housekeeping control) compared to scrambled control siRNA (p = 0.001). C) Decreased ABCD2 expression 24 hours after
transfection with miR-30d mimic (normalized to B2M housekeeping control) compared to scramble control siRNA (p = 0.047); data not shown for
ABCD2 siRNA as remaining amount of ABCD2 mRNA was no longer quantifiable by qPCR 24 hours after transfection.
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we did observe decreased ABCD2 expression 24 hours
after miR-30d over-expression. The decrease in ABCD2
following miR-30d over-expression was of much smaller
magnitude than the decrease in ABCD2 after using tar-
geted siRNA. It is likely that the moderate effect of miR-
30d on ABCD2 expression was not enough to induce a
phenotypic change large enough to be measurable with
our endpoint assay, whereas the sensitizing effect could
be seen when directly manipulating expression levels
of ABCD2 through siRNA. Measurement of apoptotic
activity was chosen as the cellular phenotype in our
functional studies because, unlike common cellular
proliferation assays (AlamarBlue and Celltiter Glo), it
is a measurement of drug-specific effect, unaffected by
cellular growth rate.
Our study also identified a potential gene target of
miR-30d, ABCD2 (ATP-Binding Cassette Sub-Family D
Member 2). ABCD2 is a member of the superfamily ofATP-binding cassette transporters (which transport vari-
ous molecules across extra- and intra-cellular membranes)
and of the ALD subfamily (involved in peroxisomal import
of fatty acids and/or fatty acyl-CoAs in the organelle).
While its function is unknown, ABCD2 is the closest
homologue of ABCD1, the mutation of which is the well
known cause of Zellweger Syndrome [29]. However, muta-
tion in ABCD2 has been shown not to confer the same
loss-of-function-related disease state [29,30]. ABCD2 has
also been shown to interact directly with PEX19 (peroxi-
somal biogenesis factor 19) [31], β-catenin, and TCF-4
[32]. To gain insight into the function of ABCD2 in cancer,
we performed gene knockdown experiments in an ovarian
cancer cell line, SKOV-3. We found that reduction of
ABCD2 expression by siRNA knockdown led to an in-
crease in apoptotic activity after treatment with cisplatin,
suggesting that ABCD2 plays a role in cellular sensitivity
to the platinums in ovarian cancers. These results are con-
sistent with a recent study which has shown that ABCD2
LaCroix et al. BMC Genomics 2014, 15:292 Page 12 of 13
http://www.biomedcentral.com/1471-2164/15/292is part of a gene expression signature with statistically sig-
nificant correlation with overall survival in ovarian carcin-
oma patients with effusions [33]. Additional studies on the
clinical relevance of our findings are therefore warranted.
Conclusions
In summary, we developed an integrative model that
incorporates multi-dimensional genomics datasets (geno-
type, mRNA, miRNA) to identify genetic variants associ-
ated with platinum sensitivity through their regulatory
effect on the transcriptome. This novel model can be
applied to the study of other complex traits. Through
our pyramid analysis, we discovered a set of SNPs, miR-
NAs, and genes which potentially comprise a function-
ally important regulatory pathway in cellular sensitivity
to the platinating agents. Functional testing supports
the function of ABCD2 and potentially miR-30d in
conferring platinum resistance.
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